Exploring the efficacy of centchroman as a postpartum contraceptive: an observational study

Bhismadev Chhatria; Lucy Das; S. Naimisha Priya; Ipsita Mohapatra; Shristy Mohanty; Subha Ranjan Samantaray

doi:10.18203/2320-1770.ijrcog20251583

Authors

Bhismadev Chhatria Department of Obstetrics and Gynaecology, PGIMER and Capital Hospital, Bhubaneswar, Odisha, India
Lucy Das Department of Obstetrics and Gynaecology, S.C.B Medical College, Odisha, India
S. Naimisha Priya Department of Obstetrics and Gynaecology, All India Institute of Medical Sciences, Bhubaneswar, Odisha, India
Ipsita Mohapatra Department of Obstetrics and Gynaecology, IMS and SUM Hospital, Campus-II, Bhubaneswar, Odisha, India https://orcid.org/0000-0002-1019-5572
Shristy Mohanty Department of Maternal Fetal Medicine, Fernandese Hospital, Hyderabad, India
Subha Ranjan Samantaray Department of Obstetrics and Gynaecology, IMS and SUM Hospital, Campus-II, Bhubaneswar, Odisha, India

DOI:

https://doi.org/10.18203/2320-1770.ijrcog20251583

Keywords:

Centchroman, Family planning, Ormeloxifene, Postpartum contraceptive, Post-delivery contraception

Abstract

Background: Centchroman, a non-hormonal contraceptive, offers a safer alternative for postpartum women, particularly in India, where the responsibility of contraception largely falls on females. Despite its benefits, including minimal side effects and efficacy in pregnancy prevention, its adoption remains low. This study examines Centchroman’s effectiveness as a postpartum contraceptive in eastern India

Methods: This prospective observational study (March 2017–February 2018) recruited postpartum women from SCB Medical College, Odisha, meeting inclusion criteria. Participants took Centchroman following a structured regimen, with follow-ups at 1, 3 and 6 months. The primary objective was to determine contraceptive efficacy. Secondary objectives were to assess compliance, satisfaction and adverse effects. Data were analysed using SPSS using Statistics (Version 23.0).

Results: During the study, 785 eligible participants were counselled and 247 consented to use Centchroman, resulting in an acceptance rate of 31.5%. Most were aged 25–29, Hindu (79.7%) and from rural areas (59.5%). Compliance was high, with 96.2% satisfaction by the third follow-up. Common adverse events included delayed periods and heavy bleeding, which decreased over time. Milk secretion reduction was minimal. The main reasons for discontinuation were living apart from their husband (4.8%) and fear of side effects (4.4%). Centchroman showed high adherence, safety and effectiveness as a postpartum contraceptive.

Conclusions: This study highlights Centchroman as a safe, effective, non-hormonal postpartum contraceptive with high acceptability. Minimal adverse effects make it suitable for lactating mothers.

Metrics

Metrics Loading ...

Author Biography

Ipsita Mohapatra, Department of Obstetrics and Gynaecology, IMS and SUM Hospital, Campus-II, Bhubaneswar, Odisha, India

Associate Professor

Department of Obstetrics and Gynecology

AIIMS Bhubaneswar

References

Srivastava U, Pandey A, Singh P, Singh KK. A study on initiation of postpartum family planning in India based on NFHS-4: does urban poor differ significantly from rural?. BMC Women Health. 2022;22(1):472. DOI: https://doi.org/10.1186/s12905-022-02042-z

Askew I, Raney L, Kerrigan M, SridharA. Family planning saves maternal and newborn lives: Why universal access to contraception must be prioritized in national maternal and newborn health policies, financing and programs. Int J Gynecol Obstet. 2024;164:536-40. DOI: https://doi.org/10.1002/ijgo.15127

Stover J, Hardee K, Ganatra B, Horton S. Interventions to improve reproductive health. 2016. Available at: https://www.ncbi.nl.nih. Accessed on 21 December 2024. DOI: https://doi.org/10.1596/978-1-4648-0348-2_ch6

Bhasin SK, Pant M, Metha M, Kumar S. Prevalence of usage of different contraceptive methods in East Delhi-a cross sectional study. Indian J Comm Med. 2005;30(2):53.

Borda M. Family planning needs during the extended postpartum period in India. Access family planning initiative brief. 2013.

Purandare BN, De Sa Souza JM. Federation of Obstetric and Gynaecological Societies of India. 2024. Avaialble at: practical-handbook. Accessed on 21 January 2025.

Roy N, Adhikary P, Kabra R, Kiarie J, Mburu G, Dhabhai N, et al. Postpartum contraceptive practices among urban and peri-urban women in North India: a mixed-methods cohort study protocol. BMC Pregnancy and Childbirth. 2021;21(1):4294. DOI: https://doi.org/10.1186/s12884-021-04294-3

Drugs and Lactation Database. Bethesda (MD): National Institute of Child Health and Human Development; 2006. Contraceptives, Oral, Combined. 2024;23(12):8364.

Kamboj VP, Ray S, Anand N. Centchroman: a safe reversible postcoital contraceptive with curative and prophylactic activity in many disorders. Front Biosci. 2018;10:1–14. DOI: https://doi.org/10.2741/e807

Singh MM. Centchroman, a selective estrogen receptor modulator, as a contraceptive and for the management of hormone-related clinical disorders. Med Res Rev. 2001;21(4):302-347. DOI: https://doi.org/10.1002/med.1011.abs

Unnithan M. Conflicted reproductive governance: The co-existence of rights-based approaches and Coercion in India’s family planning policies. Anthropologies of global maternal and reproductive health: From policy spaces to sites of practice. 2022 :117-36. DOI: https://doi.org/10.1007/978-3-030-84514-8_7

Kabra R, Allagh KP, Ali M, Jayathilaka CA, Mwinga K, Kiarie J. Scoping review to map evidence on mechanism of action, pharmacokinetics, effectiveness and side effects of centchroman as a contraceptive pill. BMJ Open. 2019;9(10):30373. DOI: https://doi.org/10.1136/bmjopen-2019-030373

Doke G, Kamda J. A study of Centchroman users with special reference to its contraceptive benefit. Int J Reprod Contracept Obstet Gynecol. 2019;8(11):4204-7. DOI: https://doi.org/10.18203/2320-1770.ijrcog20194594

Miuli I, Dewan R, Agarwal K. A study to compare acceptability, safety and continuation rates of combined hormonal pill and centchroman as post abortion contraceptives. Int J Reprod Contracept Obstet Gynecol. 2020;9(8):3350–9. DOI: https://doi.org/10.18203/2320-1770.ijrcog20203322

Milana M. Centers for Disease Control and Prevention. (n.d.). Learn the signs. Act early. Milestone checklists. Centers for Disease Control and Prevention. Retrieved April 7, 2025, from https://www.cdc.gov. Accessed on 21 Janaury 2025.

Gupta M, Bansiwal R, Anand HP. Comparison of centchroman and PPIUCD in terms of efficacy, safety and continuation rate in immediate postpartum period. Int J Reprod Contracept Obstet Gynecol. 2021;10(1):203-6. DOI: https://doi.org/10.18203/2320-1770.ijrcog20205769

Sarkar A, Wadhawan I, Raj A, Nagabhushana P, Singh P. Improving the acceptance rate of centchroman as a postpartum contraceptive through a quality improvement initiative. Cureus. 2022;14(9):29277. DOI: https://doi.org/10.7759/cureus.29277

Nair HS, Jayasimhan P. A prospective study of centchroman users with special reference to its contraceptive benefit. J. Evid Based Med Health. 2016;3(98):5374-80. DOI: https://doi.org/10.18410/jebmh/2016/1117

Mohapatra I, Samantaray SR, Soma H, Pun SK, Halder B. Knowledge and practices about family planning among women attending the Obstetrics Outpatient Department of a newly established tertiary care center. Int J Reprod Contracept Obstet Gynecol. 2022;11:2190-3. DOI: https://doi.org/10.18203/2320-1770.ijrcog20221935